Oryzon Secures Key AML Combination Patent, Bolsters Iadademstat IP
Event summary
- Oryzon Genomics has been granted U.S. Patent US12,564,559 B2 covering combinations of its LSD1 inhibitor, iadademstat, with venetoclax.
- The patent, expiring in January 2039 (including patent term adjustment), protects methods of treating acute myeloid leukemia (AML) using these combinations.
- Preliminary data from a Phase Ib clinical trial (ALICE-2) showed a 100% overall response rate (ORR) and 90% complete remission rate with iadademstat, venetoclax, and azacitidine.
- Updated data from the ALICE-2 trial, involving approximately 15-16 patients, are expected to be presented at the EHA Annual Congress in June 2026.
The big picture
The patent grant strengthens Oryzon's IP position for iadademstat, a key asset in the competitive oncology market. The combination with venetoclax, a standard of care for AML, represents a significant opportunity, but the 100% ORR data, while promising, requires further validation. Success hinges on demonstrating sustained efficacy and navigating the complexities of regulatory approval and market access in a crowded therapeutic area.
What we're watching
- Clinical Efficacy
- The June EHA presentation will be critical to validating the initial 100% ORR data and assessing the long-term durability of responses in the ALICE-2 trial, which will inform the drug's commercial viability.
- Regulatory Pathway
- The potential for further patent term extensions related to regulatory review could significantly impact Oryzon’s market exclusivity and profitability, especially given the competitive landscape in AML treatment.
- Competitive Dynamics
- How the emergence of other LSD1 inhibitors or novel AML therapies will affect iadademstat’s adoption and Oryzon’s ability to maintain a differentiated position in the market remains to be seen.
Related topics